Correlation Between Merck and Cellectis
Can any of the company-specific risk be diversified away by investing in both Merck and Cellectis at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Merck and Cellectis into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Merck Company and Cellectis SA, you can compare the effects of market volatilities on Merck and Cellectis and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Merck with a short position of Cellectis. Check out your portfolio center. Please also check ongoing floating volatility patterns of Merck and Cellectis.
Diversification Opportunities for Merck and Cellectis
Very poor diversification
The 3 months correlation between Merck and Cellectis is 0.82. Overlapping area represents the amount of risk that can be diversified away by holding Merck Company and Cellectis SA in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cellectis SA and Merck is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Merck Company are associated (or correlated) with Cellectis. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cellectis SA has no effect on the direction of Merck i.e., Merck and Cellectis go up and down completely randomly.
Pair Corralation between Merck and Cellectis
Considering the 90-day investment horizon Merck Company is expected to generate 0.39 times more return on investment than Cellectis. However, Merck Company is 2.54 times less risky than Cellectis. It trades about -0.08 of its potential returns per unit of risk. Cellectis SA is currently generating about -0.03 per unit of risk. If you would invest 12,476 in Merck Company on August 27, 2024 and sell it today you would lose (2,558) from holding Merck Company or give up 20.5% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Strong |
| Accuracy | 100.0% |
| Values | Daily Returns |
Merck Company vs. Cellectis SA
Performance |
| Timeline |
| Merck Company |
| Cellectis SA |
Merck and Cellectis Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Merck and Cellectis
The main advantage of trading using opposite Merck and Cellectis positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Merck position performs unexpectedly, Cellectis can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cellectis will offset losses from the drop in Cellectis' long position.| Merck vs. Capricor Therapeutics | Merck vs. Soleno Therapeutics | Merck vs. Bio Path Holdings | Merck vs. Moleculin Biotech |
| Cellectis vs. Eliem Therapeutics | Cellectis vs. HCW Biologics | Cellectis vs. Scpharmaceuticals | Cellectis vs. Milestone Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Complementary Tools
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |